CHEK1 and acute myeloid leukemia: ART targeting Noxa/Bim/Mcl-1/p-Chk1 axis improves drug resistance of venetoclax combined with cytarabine in AML, providing a new triple therapy for AML treatment (Zhang J. et al., 2022).